Austin Private Wealth LLC Increases Holdings in Becton, Dickinson and Company $BDX

Austin Private Wealth LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,528 shares of the medical instruments supplier’s stock after buying an additional 185 shares during the quarter. Austin Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $263,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Saudi Central Bank purchased a new position in Becton, Dickinson and Company during the first quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new position in Becton, Dickinson and Company during the first quarter worth approximately $27,000. Cornerstone Planning Group LLC lifted its position in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company during the first quarter worth $31,000. Finally, WPG Advisers LLC acquired a new stake in Becton, Dickinson and Company during the first quarter worth $36,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent analyst reports. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Royal Bank Of Canada reissued a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Piper Sandler reissued a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley raised their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $205.40.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 1,895 shares of company stock valued at $358,995 in the last ninety days. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.5%

Shares of NYSE BDX opened at $181.49 on Thursday. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a fifty day simple moving average of $189.14 and a 200-day simple moving average of $183.39. The stock has a market capitalization of $52.02 billion, a PE ratio of 32.64, a PEG ratio of 1.44 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion during the quarter. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.